Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant
January 27th 2022The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic cell transplant, indicating improvements in patient care overall.
Read More
Chemosensitivity Reflects Improved OS Following Adjuvant Chemotherapy in Gastric Cancer
January 26th 2022Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.
Read More
Durvalumab Plus Tremelimumab Improves OS in Unresectable HCC
January 18th 2022The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.
Read More
Optimized Treatment Starts With Molecular Testing in NSCLC
January 14th 2022Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.
Read More
Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL
January 14th 2022Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
GI Armamentarium Undergoes Changes With New Treatment Mechanisms and Applications
January 12th 2022Chih-Yi (Andy) Liao, MD, discusses the focus of each presentation at the webinar, which centered on optimizing therapy in advanced pancreatic cancer, the contemporary use of surgery and systemic therapy in NETs, multidisciplinary approaches to hepatocellular carcinoma, and the evolving role of liver transplant and systemic therapy.
Read More
Black Men Derive Improved Outcomes With Definitive Radiotherapy in Localized Prostate Cancer
January 10th 2022Black men with localized prostate cancer who had been treated with definitive radiotherapy had a lower likelihood of experiencing biochemical recurrence, distant metastasis, and prostate cancer–specific mortality compared with White men despite having more aggressive disease.
Read More
Immunotherapy Continues to Touch All Areas of Lung Cancer Treatment
January 9th 2022David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.
Read More
Chemotherapy-Free Regimens Seek to Replace Current Standards in Metastatic HR+ Breast Cancer
January 4th 2022Sara Tolaney, MD, MPH, discusses the data with the oral selective estrogen receptor degrader, elacestrant, and the androgen receptor agonist, enobosarm, in estrogen receptor–positive, HER2-negative breast cancer.
Read More
Zandelisib Elicits High Response Rates in Relapsed/Refractory Follicular Lymphoma
December 23rd 2021Zandelisib demonstrated significant activity and an encouraging preliminary safety profile in patients with relapsed/refractory follicular lymphoma who have received at least 2 prior systemic therapies.
Read More
FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for EGFR+ NSCLC
December 23rd 2021The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non–small cell lung cancer with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
Read More
Enobosarm Generates Overdue Excitement in AR+/ER+ Metastatic Breast Cancer
December 22nd 2021Lee S. Schwartzberg, MD, discusses the culmination of research with androgen-targeted agents in metastatic androgen receptor–positive, estrogen receptor–positive breast cancer and ongoing research that could lead to a paradigm shift in the second-line setting.
Read More
EAU Guidelines Endorse Frontline Immunotherapy-Based Combinations in Advanced RCC
December 22nd 2021Positive findings from the phase 3 CLEAR, CheckMate 9ER, CheckMate 214, and KEYNOTE-426 trials have led to the swift adoption of combination immunotherapy as the preferred frontline standard of care for the treatment of patients with advanced clear cell renal cell carcinoma, which has been further enforced by a recommendation from the European Association of Urology RCC Guidelines Panel.
Read More
Japanese Approval Sought for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
December 21st 2021A supplemental new drug application has been submitted to Japan’s Ministry of Health, Labour, and Welfare or the use of fam-trastuzumab deruxtecan-nxki as a treatment in select patients with HER2-positive unresectable or recurrent breast cancer.
Read More